Identification
- Summary
Rabies immune globulin, human is a solution of antibodies used to prevent rabies after an exposure.
- Brand Names
- Hyperrab, Imogam, Kedrab, Rabavert
- Generic Name
- Rabies immune globulin, human
- DrugBank Accession Number
- DB11603
- Background
IMOGAM Rabies Pasteurized is indicated for post-exposure prophylaxis in persons suspected of exposure to rabies, who have not previously received a complete immunization regimen with a cell culture produced rabies vaccine.
Persons previously vaccinated with other types of rabies vaccines in whom adequate antibody levels have not been demonstrated should receive full post-exposure prophylaxis with RIG and a cell culture-produced rabies vaccine.
IMOGAM Rabies Pasteurized should be administered promptly after exposure, in conjunction with rabies vaccine. If IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies vaccine. Since rabies vaccine-induced antibody begins to appear within one week, there is no value in administering rabies immune globulin more than eight days after rabies vaccination has begun.
Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory Committee on Immunization Practices (ACIP), and the World Health Organization (WHO).
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Polyclonal antibody (pAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Human rabies virus immune globulin
- Rabies immune globulin
- Rabies immune globulin (human)
- Rabies immune globulin human
- Rabies immune globulin,human
- Rabies immunoglobulin (human)
- Rabies immunoglobulins
Pharmacology
- Indication
The human rabies immune globulin is used indicated for passive, transient post-exposure prophylaxis of rabies infection to persons of all ages when given immediately after contact with a rabid or possibly rabid animal. It should be administered concurrently with a full course of rabies vaccine.1
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Adjunct therapy in prophylaxis of Rabies •••••••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Rabies immune globulin prevents viral invasion of the central nervous system.
- Mechanism of action
Rabies immune globulin binds the rabies virus, preventing it from invading the central nervous system Label. This affords time for the rabies vaccine, which is also administered in cases of rabies exposure, to induce an immune response to destroy the virus. Rabies immunoglobulin should only be administered up to eight days after exposure as the host begins to produce sufficient antibodies to the virus one week after exposure. Repeat dosing should also be avoided as it may interfere with induction of immune response by the rabies vaccine.
Target Actions Organism ARabies Virus Proteins antibodyRabies virus (strain Pasteur vaccins / PV) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
No toxicological studies have been performed. Isolated cases of angioneurotic edema, skin rash, nephrotic syndrome, and anaphylactic shock after injection have been noted Label.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Alemtuzumab. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Hyperab Rabies Immune Globulin Human Liquid 16.5 % Intramuscular Cutter Med & Biol, Division Of Miles Canada Ltd. 1985-12-31 1998-09-25 Canada 
HyperRAB Solution 300 unit / mL Intramuscular Grifols Therapeutics Llc 2019-07-02 Not applicable Canada HyperRAB Injection, solution 300 [iU]/1mL Infiltration; Intramuscular GRIFOLS USA, LLC 1974-06-12 Not applicable US 
Hyperrab S/d Injection 150 [iU]/1mL Intramuscular GRIFOLS USA, LLC 1996-08-14 Not applicable US Hyperrab S/d Solution 150 unit / mL Intramuscular Grifols Therapeutics Llc 1997-10-09 2022-07-08 Canada
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 95F619ATQ2
- CAS number
- Not Available
References
- General References
- FDA Approved Drug Products: KEDRAB [Rabies Immune Globulin (Human)] solution for wound infiltration and intramuscular injection [Link]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Basic Science Rabies 2 4 Terminated Treatment Primary Immune Deficiency Disorders (PIDD) 1 4 Withdrawn Prevention Viral Disease 1 3 Active Not Recruiting Prevention Viral Disease 1 3 Completed Prevention Children, Only / Malaria caused by Plasmodium falciparum 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Parenteral 200.00 - Injection, solution Intramuscular Solution Intramuscular; Subcutaneous 1000 iu/5ml Liquid Intramuscular 16.5 % Injection, solution Infiltration; Intramuscular 300 [iU]/1mL Solution Intramuscular 300 unit / mL Injection Intramuscular 150 [iU]/1mL Solution Intramuscular 150 unit / mL Injection Infiltration; Intramuscular 150 iu/ml Liquid Intramuscular 150 unit / mL Solution Parenteral 750.000 UI Injection, solution Intramuscular 150 [iU]/1mL Powder, for solution Intramuscular 2.5 IU/mL Injection, powder, for solution Intramuscular 1 ml Injection, powder, for solution Intramuscular 2.5 IU Solution Parenteral 300 UI Solution 150 IU/ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
- Kind
- Protein group
- Organism
- Rabies virus (strain Pasteur vaccins / PV)
- Pharmacological action
- Yes
- Actions
- Antibody
- General Function
- Attaches the virus to host cellular receptor, inducing endocytosis of the virion. In the endosome, the acidic pH induces conformational changes in the glycoprotein trimer, which trigger fusion between virus and cell membrane. There is convincing in vitro evidence that the muscular form of the nicotinic acetylcholine receptor (nAChR), the neuronal cell adhesion molecule (NCAM), and the p75 neurotrophin receptor (p75NTR) bind glycoprotein and thereby facilitate rabies virus entry into cells (By similarity).
- Specific Function
- Not Available
Components:
| Name | UniProt ID |
|---|---|
| Glycoprotein | P08667 |
| Large structural protein | P11213 |
| Matrix protein | P08671 |
| Nucleoprotein | P06025 |
| Phosphoprotein | P06747 |
References
- Sikes RK: Human rabies immune globulin. Public Health Rep. 1969 Sep;84(9):797-801. [Article]
- Franka R, Carson WC, Ellison JA, Taylor ST, Smith TG, Kuzmina NA, Kuzmin IV, Marissen WE, Rupprecht CE: In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3). pii: tropicalmed2030048. doi: 10.3390/tropicalmed2030048. [Article]
Drug created at June 01, 2016 20:49 / Updated at April 22, 2024 14:28